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Abstract 
 
 
 Cardiovascular disease is the number one leading cause of death in the United States. A 
myocardial infarction is the medical term for what is commonly known as a heart attack. 
Myocardial infarctions are caused by cardiovascular disease and more specifically, by the 
blocking of a main artery in the heart. A team of students and professors at Worcester 
Polytechnic Institute designed a device and method for producing tissue engineered blood 
vessels (TEBVs), which are proposed to be a new and effective treatment for coronary artery 
bypass surgery. The purpose of this study was to decide whether TEBVs were a worthwhile 
commercial venture by performing a number of analyses. Currently, the method to produce the 
TEBVs is still being altered and the grafts are still in the early development stages. It was 
determined, however, through the analyses that TEBVs are a worthwhile venture to invest in due 
to the high demand in the cardiovascular disease treatment market.  
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Executive Summary 
 
 
 Cardiovascular disease claims the lives of over 80 million people each year.
1
 Globally, 
there are over 800,000 coronary artery bypass graft (CABG) procedures annually.
2
 Due to the 
high occurrence of such procedures each year, the need for new treatments and procedures 
continues to rise. The current treatments include: 
 
 Autografts 
 Allografts 
 Synthetic Grafts 
 
 There are a number of problems with the aforementioned treatments. These issues have 
brought about the need for alternative source of materials for cardiovascular disease. Section 4.1 
reviews the current treatments and also introduces a new alternative treatment known as tissue 
engineered blood vessels (TEBVs).  
 A Worcester Polytechnic Institute project team from 2010 was posed with the challenge 
of designing a method for the tubular self-assembly of cells to create a TEBV. Currently, there 
are a few organizations/companies producing TEBVs; however, the time it takes to produce one 
TEBV is one of the main constraints in the production process. This constraint was also a 
constraint for the WPI project team and without a front-end processing period and post-
maturation period, the project team was able to build a vessel within a three day period. The 
aforementioned periods are part of a four phase TEBV production process that is highlighted in 
section 4.3.3.  It is believed that TEBVs would provide a treatment alternative for CABG 
procedures.  
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 This report was produced in part by the management department and the biomedical 
department at WPI. It was designed to analyze the business factors related to TEBVs and 
whether TEBVs are a worthwhile venture in which to invest. The investigation focused on the 
cardiac market but more importantly, the target markets in which the TEBVs would be marketed. 
This investigation was performed under the assumption that WPI will first sell a “plug and play 
kit” to generate enough revenue to gain FDA certification for the TEBVs for in-vivo 
applications. This report provides an analysis of: 
 Cardiovascular disease  
 Current treatments 
 Alternative graft source such as TEBVs 
 WPI TEBVs and process  
 A business model 
 A cost analysis on the “plug and play kit” design idea  
 A cost analysis on the TEBVs 
 A SWOT Analysis 
 A Market Analysis 
   
 Through the aforementioned analyses, it was determined that the TEBVs produced at 
WPI have a promising future. It is important that WPI and the inventors of this technology begin 
collecting test data on the TEBVs to provide the FDA with the necessary data to gain approval 
for clinical applications. The proposed business model, as seen in Chapter 3, states that the 
inventors should first sell the kits to begin generating revenue. With the generated revenue, the 
inventors can then fund the testing necessary to gain FDA approval for clinical applications. The 
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author believes that once the TEBVs are FDA approved, TEBVs will become the industry 
standard for the CABG procedure.  
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1. Introduction/Problem Statement 
 
 Cardiovascular diseases are among the leading causes of death in adults world-wide. In 
2006, there were 80 million people in the United States who were reported to have some type of 
cardiovascular disease.
1 
Cardiovascular diseases are caused by a number of factors such as the 
buildup of fatty material in arteries, smoking, and triglycerides.
1
 When fat and cholesterol build 
up in the arteries, the build-ups begin to block blood flow, ultimately resulting in cardiovascular 
disease and heart attacks.  
 Myocardial infarction, also more commonly referred to as a heart attack, is one of the 
effects of cardiovascular diseases. Heart attacks claim the lives of over one million people 
annually.
1
 According to the American Heart Association (AHA), there are over a million 
coronary heart attacks in the United States per year. In many cases, when a patient is admitted to 
a hospital, the surgeon will use a stent to clear the blocked arteries of the patient in order to allow 
blood to flow to the heart; a stent is essentially an artificial tube implanted in the body to 
temporarily reduce the constriction of fluid flow. This technique, however, has proven to fail 
when restenosis occurs and there is a need for alternative methods to curing cardiovascular 
diseases. Restenosis is a condition that affects about 30% of patients who have undergone the 
aforementioned procedure and is essentially when the artery becomes blocked again within a few 
months post surgery. 
 Another method for treating cardiovascular disease is through the procedure of CABG. In 
this procedure, surgeons will generally harvest the saphenous vein which is a large vein found in 
the patient’s leg. The harvested saphenous vein is then implanted in place of the clogged artery 
allowing blood to once again flow to the heart. There are also problems with this procedure 
however. Lasting pain and scars from the surgery as well as a poor 10 year failure rate have 
12 
 
caused surgeons to use this method in only the most severe cases of cardiovascular disease.
3
 
During this procedure, surgeons bypass the blocked coronary artery. CABG surgery can be 
performed using a number of graft source materials including: 
 Autografts 
 Allografts 
 Synthetic Grafts 
 Tissue Engineered Blood Vessels (TEBVs) 
 
This technique has failed up to 50% within the first ten years for a number of reasons including 
the formation of neointima.
3
 This condition is considered a new and thickened layer within the 
artery formed on a prosthesis.  
 There are also other methods currently in use to help treat clogged arteries. Other than 
using the saphenous vein, doctors’ use artificially created blood vessels that share many 
properties with real living tissue. There are, however, disadvantages to using the synthetic 
materials. For example, synthetic arteries have a high tendency to clot again within a few years 
following implantation and may actually clog at a higher rate than natural arteries.
4
 There is a 
clear need for a substitute to the current graft materials. 
 Blood vessel tissue engineering is a recent art in which scientists use living cell cultures 
to create living blood vessels for a variety of applications. Although there are a number of 
advantages associated with using tissue engineered blood vessels, there are also a number of 
disadvantages that challenge the viability of the technology. Currently, it takes a long time to 
produce engineered tissues from cell biopsies.
5
 This constraint has led to the need for a more 
timely method to produce cell-based tissue engineered blood vessels.     
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 A Major Qualifying Project (MQP) team from Worcester Polytechnic Institute was able 
to develop a method and technology for the tubular self-assembly of cells to create a tissue 
engineered blood vessel (TEBV).
6
 With this technology, the project team was able to 
successfully engineer a group of living cells into a living blood vessel that could be used for a 
number of real world applications. One of the group’s main concerns was to produce the 
engineered blood vessels in a significantly shorter period of time than the current clinical trials. 
Cytograft, a producer of TEBVs, has a TEBV production process that takes nearly 24 weeks to 
complete.
5
 By shortening the time to produce a TEBV, the WPI technology would then be a 
more attractive product and thus gain a competitive advantage against other companies within 
the market. 
 There are many applications in which these engineered blood vessels can be used. One 
idea developed by the biomedical department at WPI was to design a kit that would allow 
scientists, doctors, and other stakeholders to produce the TEBVs within their own laboratory for 
the desired application. The idea of the kit was introduced by Professor Marsha Rolle of the WPI 
Biomedical Engineering department. Essentially, the kit would allow scientists with little 
experience of the technology to create living tissue within their own laboratory. The kit would 
include the required means to produce the TEBVs along with an instruction manual explaining, 
in detail, the required processes to produce the TEBVs.  
 Although this technology is new and useful, there are many factors to consider when 
understanding the biomedical industry. This paper focuses on the benefits of pursuing a company 
in which the main revenue will be generated through the sale of TEBVs and a manufactured kit 
to produce TEBVs. A block diagram (Figure 1) shows the life cycle of the product produced at 
WPI from the sale of a kit to the sale of TEBVs. The author proposes that WPI first sell the kit 
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that will be marketed as a research tool. The revenue generated from selling the kits will be used 
to research and study the long-term patency and efficacy of the TEBVs thus providing ample 
research to obtain insurance reimbursement codes and FDA approval for in-vivo use.  
 
Figure 1: Block Diagram of the Life Cycle of the WPI Product. 
 
 To understand the factors that will ultimately affect the sale of TEBVs, the following 
analyses were completed: 
 An analysis of the industry  
 An analysis of the competition 
 An analysis of risk factors 
 An analysis of FDA regulations  
 An analysis of  the barriers to entry  
 An analysis of the stakeholder’s involved 
Kit with needed 
components to produce  
TEBVs designed and 
marketed
Kit sold as research tool for 
labs studying disease 
treatments to produce 
living tissue within their 
lab
TEBVs produced by kit 
studied for long-term 
patency and efficacy
Data from research used 
to obtain insurance 
reimbursement codes and 
FDA approval for in-vivo 
use
TEBVs produced from kit 
sold for use in human 
subjects
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 A market segmentation analysis 
  Following the analysis of these factors, the author garnered an in depth understanding of 
the product as well as its marketability. This report and analysis provides a number of 
recommendations as well as a target investment value that will be necessary for entry. The goal 
of this report was to provide investors with an in-depth understanding of the product and its 
ability to succeed in a competitive market place.  
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2. Methods/Procedures 
 
 To successfully determine the marketability of TEBVs, an in-depth analysis of both the 
kit and TEBVs ability to compete in the market was conducted. It was important to assess the 
costs associated with producing TEBVs as well as the costs associated with the kit. It was also 
important to understand the market position of the TEBVs. To further understand these concepts, 
the author completed a comprehensive literature review. The author also conducted interviews 
with professionals to garner a more in-depth practical view on TEBVs and their marketability 
(Figure 2).   
 
 
Figure 2: Report Methodology- Inputs and Final Output 
  
   An in-depth review of scholarly articles, medical journals, legal documents (including 
patents), regulatory documents released by the FDA, and market statistics and sources was 
essential to understand the separate issues regarding the technology.  
Final Marketability Analysis for 
Tissue Engineered Blood Vessels
Personal 
experience 
and 
expertise
Interviews 
with 
Professionals
Comprehensive 
Literature 
Review
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 During the research stage of this report, interviews were conducted with professionals 
within separate fields relative to the nature of the topic, e.g.:  biomedical engineers for the 
technology, and a mechanical engineer from a manufacturing plant. The information obtained 
from these analyses was used when making final recommendations for the viability and 
marketability of TEBVs. Additionally,   the author conducted both a S.W.O.T. analysis 
(strengths, weaknesses, opportunities, and threats) of the technology and a cost-benefit analysis.    
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3. Results 
 
 Based on the assumption that FDA approval for the use of TEBVs in clinical applications 
will be obtained, it is expected that the TEBVs will have significant market potential in the 
treatment for cardiovascular disease. This is partially based on the fact that each year, there are 
over 800,000 coronary artery bypass grafts performed.
2
 Due to the high frequency of procedures, 
it is likely that the demand for a product of this nature is very high.  
 Through the analyses throughout this report, it is seen that the TEBVs produced at WPI 
are similar but not the same as any other technology in the market. There are companies and 
laboratories producing and testing TEBVs; however, one main constraint of TEBVs is the time it 
takes to produce one unit. At this point, the WPI process has a favorable time to produce which 
will prove to be important when marketing the TEBVs. Although it is not possible to calculate a 
payback period for TEBVs, it can be assumed that with the high demand (over 800,000 CABG 
procedures annually) for treatments for cardiovascular disease, the payback period will be within 
the first year. As stated in the break-even analysis in section 4.3.6, WPI or a company based 
from the WPI technology will only need to produce and sell 17 TEBVs to break-even with an 
initial investment of $100,000. This can also be seen in Appendix 8.4. 
 It is recommended that WPI use the technology and TEBVs to create a start-up company 
following the review of the medical supplies and devices industry, the pharmaceuticals 
manufactured industry, and the benefits of starting a company versus licensing the technology. 
There is promising potential for growth and expansion in both target industries. As stated in 
section 4.4.5, the percentage of compensation WPI would receive through a licensing partnership 
is very low compared to the potential earnings of a start-up company. 
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Proposed WPI TEBV Business Model 
 
 The proposed WPI TEBV business model is a two phase process. The two steps are used 
to ensure that the needed funds are obtained for FDA certification of the TEBVs for clinical 
applications. Phase one of the process includes the sale of the TEBV-producing kits, as proposed 
in section 4.3.2. The idea behind this phase of the business model is that the proposed company 
will produce and sell the kits for use in medical research. Phase 2 of the business model is the 
sale of TEBVs. A schematic of the business model can be seen below (Figure 3).    
 
Figure 3: Proposed Business Plan Flow Chart 
 Figure 3 depicts the process flow of each phase of the proposed business plan. During 
phase one of the proposed business model, the business will sell the kits to medical research 
firms and/or universities. By doing so, it is expected that the business will generate the needed 
revenue to perform clinical research on the TEBVs produced from larger scale versions of the 
kit. The clinical research performed on the TEBVs will then be used to gain FDA approval for 
clinical use of the TEBVs. It is mentioned in L’Heureux’s study that there is a need for 4-6 years 
of data to prove a product is cost effective.
5 
Once the TEBVs are approved for clinical use, the 
final phase of the business plan will be to sell the product to hospitals/surgeons.  
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 To generate the interest and demand in the product, the company will first need to 
successfully market the product. This can be done through a number of mediums including 
scholarly articles, medical journal reports/articles, and medical supply and device catalogs. The 
use of a lease program during the initial stages of the start-up company can also be an effective 
means to delivering the product to the more customers.  
Lease Program 
 
 As a start-up company, there are going to be many challenges associated with 
successfully marketing the new product. The basic idea of this process is that the company would 
first need to produce between 10 and 20 units. Upon completing the manufacturing process, the 
company would then advertise to the target market through the means of industry catalogs and 
biomedical expos. The main advertising campaign in the early stages of the company would be 
to lease the products to users for a free 30-60 day trial giving the user ample time to collect 
sample data. Once completing the lease, the user would then have both the data and experience 
to determine whether the device is necessary to their research. There would then be two options 
available to the lessee: 
   
1) To purchase the current leased product.  
 
2) To return the item and purchase a new product. 
  
 
 The company would also need to have the lessee sign a contract stating that they would 
not allow other laboratories to sell the product and also would protect WPI from any misuse or 
potential injury caused by the product. If WPI is able to generate enough revenue through the 
sale of the kit to receive FDA approval for the TEBVs, the author feels that it would be a 
worthwhile venture for investors to pursue.    
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4. Discussion 
4.1 Coronary Heart Disease and Treatments 
 
4.1.1 Coronary Heart Disease 
 
 Coronary heart disease is one of the leading causes of heart failure because the coronary 
artery fails to provide the heart with the required nutrients to continue functioning normally. As 
time passes with this lack of nutrients, the contractile portions of heart muscle begin to die 
causing what is known as a myocardial infarction, or a heart attack. The simulated drawing 
below (Figure 4) shows how a clogged left coronary artery causes a portion of the heart to die 
due to lack of nutrients and blood flow. 
 
Figure 4: Coronary Heart Disease- Blockage of the Left Coronary Artery 
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  As stated in the introduction, most heart attacks are treated using a stent.
7
 With this 
method, a stent is inserted into the clogged artery and then used to push the clotted material 
against the walls of the artery, thus allowing blood flow to return to normal levels. There are 
disadvantages to using a stent, however, such as the failure rate. In 21% of cases in an 
experiment reported by the New England Journal of Medicine, when a stent is used, the artery 
becomes blocked again just hours after surgery.
8
 There are other alternatives to using stents to 
treat cardiovascular disease. 
  Grafts are another common treatment used to combat cardiovascular disease. The 
dictionary definition of a medical graft is, “a piece of skin, bone, or other living tissue 
transplanted or to be transplanted from one body, or place on a body, to another, where it grows 
and becomes a permanent part.” Grafts are commonly used in the treatment of cardiovascular 
disease; more specifically, coronary artery bypass grafts are used to treat blocked arteries. 
4.1.2 Autografts  
 
 Coronary artery bypass grafts (CABGs) are used in treating coronary heart disease. In 
severe cases of coronary heart disease, surgeons will use the saphenous vein, located in the leg, 
as a graft for use in the heart. The saphenous vein is inserted in place of the clogged artery, 
allowing blood flow to return to normal levels. There are disadvantages to CABG surgery, 
however, such as continued internal bleeding after 24 hours post surgery, heart rhythm 
disturbances, and a relatively high 10 year failure rate. According to a report by Medicine Net, 
an online database including information and data regarding medical procedures, 44% of CABGs 
fail within 10 years post surgery due to clotting that occurs within the grafted saphenous vein.
7
 
Due to the high failure rate, there is a clear clinical need for a new method for treating 
cardiovascular disease. 
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 Autografts are a potential option for surgeons when treating cardiovascular disease. An 
autograft is a procedure in which surgeons use a vein or artery from the patient as a bypass of the 
clotted artery causing cardiovascular disease. There are two different sites that surgeons 
generally harvest grafts from to bypass the clotted artery. The first is the saphenous vein located 
in the leg of the patient. The second artery used by surgeons is the internal mammary artery, 
located in the thoracic cavity of the chest.
7
 There are advantages to both grafts; however, there 
are a number of disadvantages associated with both procedures that bring about the need for an 
alternative method for cardiovascular disease treatment. 
 Internal mammary artery grafts (IMAs) are also used in treating coronary heart disease. 
Surgeons will extract the internal mammary artery from the thoracic cavity in the chest. It is 
noted, however, that approximately 40% of patients do not have vessels available for harvest due 
to factors such as age and disease.
9
 
4.1.3 Allografts 
 
 Allografts are another potential option for surgeons when treating cardiovascular disease. 
Allografts are similar to autografts in that they use real living tissue; however, an allograft is a 
tissue or organ transplant, usually from a cadaver donor, to a patient (host). Allografts have a 
number of complications that make them a less viable option for treatment versus the other 
known treatments. Due to the different gene type of the donor, the host is susceptible to graft 
versus host disease.
10
  
 “Graft versus host” disease is a condition in which the host’s body rejects the implanted 
organ or tissue. Leukocytes, also known as white blood cells, recognize the graft due to foreign 
antigens surrounding the surface of the organ/tissue. The leukocytes then attack and destroy the 
organ or tissue causing the graft to fail. This then presents a need for another organ transplant. 
24 
 
There are methods to combat this condition through the use of drugs; however, the drugs used 
cause the body to stop recognizing antigens thus making the patient highly susceptible to other 
diseases and air borne illnesses. This is due to the lowered immune response because the body is 
attacking the graft. These drugs are dangerous because the patient loses the ability to fight and 
overcome illnesses leading to potentially fatal complications.
10
  
4.1.4 Synthetic Grafts 
 
 Synthetic grafts are an alternative to auto- and allografts. Synthetic grafts are commonly 
fabricated using polymer materials such as Teflon and the synthetic fiber Dacron. Unlike 
allografts with graft host disease, synthetic grafts are not rejected by the human body; There is 
however, a foreign body response. With Dacron grafts and other similar materials, it is unlikely 
that a detrimental foreign body response will be experienced.
11
 Although synthetic grafts 
eliminate the risk of “graft versus host” disease, there are a number of other potential 
complications that make them less viable than other alternatives. 
 Synthetic blood vessels have a higher tendency to clot than natural vessels within a three 
year period post-surgery.
9
 Reasons for this include the fact that synthetic blood vessels lack the 
same endothelial layer as natural blood vessels. Because of this, materials floating within the 
blood stream cause thrombosis to synthetic vessels at a higher rate than in natural vessels. This 
problem is often seen in smaller diameter grafts. Larger synthetic arterial grafts generally work 
and have acceptable patency rates; however, smaller grafts with diameters less than 6mm have 
lasting patency rates below 50%.
11 
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4.2 Tissue Engineered Blood Vessels 
 
 The concept of engineering tissues, and, more specifically, blood vessels, has been a 
scientific art on the rise. Through the research conducted for this report, the author believes that 
TEBVs will one day be the benchmark for cardiovascular disease treatment. Currently, there are 
a number of methods being used to produce TEBVs; however, one key constraint in most 
methods is time. This time constraint is caused by another one of the critical constraints in 
producing TEBVs.  The time needed to ensure that the mechanical properties of the TEBV are 
suitable for use in humans extends the overall production time. The two main methods for the 
creation of TEBVs are reviewed in this section including both scaffold-based TEBVs and 
completely cell-based TEBVs.  
4.2.1 Scaffold-Based Tissue Engineered Blood Vessels 
  
 Scaffold-based TEBVs are currently the most commonly made living vessels. 
Autologous skin cells, obtained from skin biopsies, are seeded onto a tubular shaped scaffold 
which is used as a device for structural support. One advantage to scaffold-based TEBVs is their 
ability to form tissues in vitro in a very short time frame yet maintain all of the required 
mechanical properties of a native tissue. Another advantage to scaffold-based TEBVs is that they 
inhibit thrombosis if endothelial cells are present, meaning that they do not clot at a higher rate 
than native tissue such as the synthetic grafts previously described
12
 Finally, by using the 
scaffold, scientists can seed smooth muscle cells on one side of the scaffold and also seed 
endothelial cells on the other side. By doing so, the vessel created shares many similar qualities 
to an individual’s native tissue. 
 There are also a few disadvantages to scaffold based TEBVs.  A disadvantage to note is 
the time it takes to produce a TEBV from a scaffold.   Currently, studies show that scaffold based 
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TEBVs tend to take up to 2-3 weeks for the vessels to completely mature and be ready for 
implantation.
6
 Cell-based TEBVs take longer to produce due to the time needed for the cells to 
produce the necessary structural properties. Although scaffold based TEBVs have advantages 
that make them more viable than the aforementioned alternatives, there remains the need for a 
more effective method to produce patent vessels.     
4.2.2 Cell-Based Tissue Engineered Blood Vessels 
 
 Completely cell-based TEBVs have many advantages, making them the focal point of 
many studies regarding tissue engineering. These cell-based tissues have high value in that they 
are the closest alternative to native tissue. One main advantage to cell-based TEBVs is the 
absence of any foreign or synthetic material. Synthetic materials allow for raised rates of 
infection, immune response, inflammation, and graft rejection.
6
 Another advantage to note is that 
TEBVs have an extremely low thrombosis rate, meaning that they do not clog easily. 
  Completely cell-based TEBVs arrange themselves into a tubular structure and are then 
implanted in vivo without the use of any scaffold. One of the most popular current methods to 
produce cell-based TEBVs is through a process called “sheet based” tissue engineering. The 
general concept of this process is that the cells are laid in a sheet like structure and are allowed to 
culture for 6-8 weeks. The sheet is then cut and rolled around a cylinder and allowed to mature in 
culture for another 12 weeks. There are a few disadvantages with this method. First, the method 
produces TEBVs that are not necessarily homogenous, meaning   that the sheets are not equally 
thick in all areas leaving some sections of the TEBVs weaker than others.
13
 These weak areas 
can cause problems to the host in that the vessel may burst or tear in the weakened areas. The 
other glaring disadvantage with this method is the time to produce.   Solving this time constraint 
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and lowering the time to produce a TEBV was one of the main objectives for the project group at 
Worcester Polytechnic Institute.
6 
4.2.3 Worcester Polytechnic Institute Tissue Engineered Blood Vessels 
 
 A Major Qualifying Project (MQP) team from Worcester Polytechnic Institute was able 
to develop a method and technology for the tubular self-assembly of cells to create a tissue 
engineered blood vessel. With this technology, the project team was able to successfully 
engineer a group of cells into a living blood vessel that could be used in treating cardiovascular 
disease. One of the main objectives of the WPI project   was to have this process take seven days 
or less. The process also needed to be reproducible, require minimal manipulation, and be easy 
for the user to remove the living tissue. It is interesting to note that the TEBV production process 
requires minimal manipulation, resulting in less chance of contamination from the workers as 
well as a lowered chance for human error.
6
 The group was able to meet these objectives. The 
group placed living cells within a polycarbonate tube, spun it for fifteen minutes at a designated 
speed, allowing the cells to distribute evenly around the inner wall of the tube. The tube was then 
placed in an incubator for three days allowing the cells to form a cohesive tissue construct.  
 The method and device designed at WPI takes advantage of the centrifuge, a device used 
to separate cells from media in a cell suspension. The group used a polycarbonate cylinder filled 
with cells and media. This cylinder was then spun using a small motor for fifteen minutes. 
During the fifteen minute cycle, the cells within the polycarbonate cylinder were “pelleted” to 
the inner diameter of the cylinder. The cells then aggregated together and created a tubular tissue 
construct which was removed from the tube and placed in a bioreactor for three days. The three 
day incubation period allowed the cells to grow with continuous nutrients through the form of 
28 
 
cell media. In Figure 5, one can see a schematic showing conceptually how the cells pellet 
against the inner diameter thus causing the cells to form a cylindrical tubular shape. 
 
Figure 5: MQP Group Centrifugal Force Design.6 
   
4.2.4 Main Applications 
 
 Clinical applications are the most likely end result for the WPI TEBVs. There are Food 
and Drug Administration (FDA) regulations governing the use and sale of medical devices and 
products which will initially limit the products applications, which are reviewed in section 4.3.3. 
Because of these regulations and the high costs associated with approving a product, the author 
decided that research is the most viable application for a start-up company revolving around the 
WPI TEBVs.  
 The device designed at WPI could potentially provide many advantages to the drug 
research field. Drug producing companies in the pharmaceutical industry could use the device to 
produce sturdy living vessels for testing new cardiovascular disease treatments. Research 
laboratories at universities and hospitals could use the vessels to better understand the effects of 
different diseases on human blood vessels.  
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4.2.5 Secondary Applications 
 
 As stated above, strict FDA regulations and the high costs associated with approving a 
product make it difficult to start a company with a product that is used in vivo, or in other words, 
on human subjects. Although a start-up company may not be able to afford the costs associated 
with certifying a device with the FDA, it is important to note that the long term business plan for 
the WPI device is aimed toward clinical applications of the TEBVs. The company would first 
focus on selling TEBV producing kits to generate enough revenue to eventually approve the 
TEBVs through the FDA. This would open an entirely new market to sell the product for clinical 
applications. 
4.2.6 Initial Design Materials 
 
 The materials used in designing and manufacturing the current model of the device at 
WPI are relatively simple. The project team from 2009 fabricated a three part system utilizing a 
cell suspension tube, a small 3 volt hobby motor, and a custom bioreactor for cell incubation. 
The cell suspension tube was created by using a lathe and a 3/8” diameter piece of polycarbonate 
plastic. The polycarbonate rod was cut into 3” units creating a tube. (Figure 6).  
 
Figure 6: Polycarbonate Tube Cut to Shape by WPI Project Team.6 
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Polycarbonate Tube 
 
 The 3” polycarbonate tube of 3/8” diameter was then drilled with a lathe to produce a ¼” 
diameter hole through the center of the tube that reaches a depth of ¾”. The other end of the tube 
was then drilled with a 1mm diameter hole that was ¼” deep for insertion of the motor. The 
polycarbonate plastic was an appropriate material for the tube due to its high melting point and 
structural properties. The high melting point is important because it allows the unit to be 
autoclaved, which is an effective method of sterilization. The final step of assembly for the 
polycarbonate tube was to fill the open end cap on the top with silicone glue. This was done to 
seal the top of the tube to ensure the cell suspension would be contained within the tube. The 
glue set within 24 hours and the tube was ready to use.  
Hobby Motor 
 
 The motor used to spin the polycarbonate tube is a basic 3-volt hobby motor. The project 
team clamped the hobby motor into a three point clamp stand (Figure 7), which held the motor in 
place allowing it to spin the polycarbonate tube. Finally, a battery pack was used to house two 
AA batteries which were clamped with alligator clamps to power the motor. These components 
were all used in a Biosafety Cabinet to ensure a sterile work space.  
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Figure 7: WPI device consisting of the battery pack with two AAs, the alligator clips to power the motor, the 3 volt hobby 
motor, the three point clamp stand, and the polycarbonate tube attached to the motor.6 
 
Incubation Chamber 
 
 The final aspect of the WPI device was the incubation chamber. The chamber was 
fabricated using a 50 mL conical tube, a T-75 gas exchange screw top, a three-way stopcock, and 
a 5 mL syringe.
6
 The project team drilled a hole in the bottom of the conical flask to allow gas to 
diffuse through the top cap. The incubation chamber can be seen below (Figure 8). 
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Figure 8: WPI Incubation chamber.6 
 
4.2.7 Future Manufacturing Techniques 
 
 Due to the raw experimental form of WPI device, there are a number of additions and 
upgrades that the device will need to have to gain commercial value. Currently, the design, as 
seen in the previous figures, shows that the device is in its simplest form. There are several 
aesthetic upgrades as well as functional upgrades that will need to be made in order to 
successfully produce a product that is market ready. The most important of these upgrades will 
be the implementation of an encased hobby motor. This will eliminate many of the risks of injury 
due to the motor. It will also eliminate the need of the alligator clips (Figure 7). Finally, the end 
product of this process, the TEBVs, will need to be manufactured on a larger scale so that they 
meet the specifications of a native blood vessel.  
 
3 Volt Hobby Motor 
 
 As previously stated, the WPI project team from 2009 used a 3 volt hobby motor to spin 
the cylindrical tube containing the cell suspension. The 3 volt hobby motor will still be sufficient 
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for spinning; however, it will need to be encased in a plastic box to ensure safety to the user and 
add aesthetic value. The group has decided that the batteries and battery pack should be 
eliminated to reduce cost for the user. By eliminating this component, however, there needs to be 
an alternate power source to run the motor. The group decided that the most efficient, user-
friendly and safe approach to solving this dilemma is to power the motor with an AC plug and 
wall outlet, similar to those used in household appliances.  
Bioreactor 
 
 During a personal communication with Professor Marsha Rolle, it was decided that the 
most applicable and marketable bioreactor at this stage of the research would be a self-contained 
bioreactor within the polycarbonate spinning cylinders. With this design, the polycarbonate 
spinning cylinder seen in Figure 6 above would include an in-flow tube and an out-flow tube. To 
feed the cells, one would simply pump cell media through this closed circuit in which the cells 
would continually receive media. This would reduce the overall cost of a kit by eliminating the 
bioreactor since it would be included within the cylinder. 
4.2.8 Packaging Techniques 
 
 When the WPI TEBV manufacturing process is completed, the product will then need to 
be packaged for shipping to the customers. The kit will be an enclosed case with a snap-lock 
closing mechanism to hold all components within the case, as seen in Appendix 8.1. Included 
within the case will be the 3 volt hobby motor component with AC power, a “starter pack” of 
polycarbonate cylinders with specified amounts of cylinders such as 25, 50, 75, or 100 pieces, a 
syringe for cell implementation, a bioreactor for cell culture and incubation, and a user manual. 
The user manual will be the key component of the kit and will be one of the main selling 
attractions of the product in that it will enable users to produce TEBVs within their own 
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laboratories. The TEBVs produced from this kit will need to be transported using a cell incubator 
in order to keep the cells alive when they travel from “bench to bedside,” meaning that the 
TEBV will be transported from the laboratory directly to the patient. 
4.2.9 Secondary Market Opportunities 
 
 Clearly, the most profitable part of the company will be the manufactured TEBVs. This, 
however, will be a future form of revenue as the company will first need to generate revenue 
through the sale of the kit. The author also realized that there was another market opportunity 
created through the use of this device. The polycarbonate cell cylinders that are used to sustain 
the cells while they are being spun will eventually be thrown away following the completion of 
the TEBV growth. The group will use this disposal of the polycarbonate cylinders to the 
company’s advantage by recommending the sale of additional packages of the cylinders.  
4.3 Cost Analysis 
 
4.3.1 Stakeholders Analysis 
 
 The stakeholders analysis is used to determine the members, groups, or organizations 
involved with the successes of a given product. A pyramid diagram can be used to rank the 
importance of a list of items. This pyramid diagram, in particular, informs the user of the most 
important groups affected by the TEBVs and kit produced at WPI. In the stakeholder diagram 
(Figure 8), the stakeholders at the top of the pyramid have the most at stake and are thus the most 
important. The market benefit of each stakeholder category is discussed in this section. 
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Figure 9: Stakeholders Pyramid 
Patients 
 
 Patients are the highest ranked stakeholders in the stakeholders pyramid because they are 
end users of the product. Patients have the most to gain from TEBVs. If the TEBV producing kit 
introduced by WPI is approved through the FDA (see section 4.3.3) and receives the proper 
codes for health insurance reimbursement (see section 4.4.9), then clinical applications will 
become a possibility allowing surgeons to use TEBVs as a treatment for cardiovascular disease. 
Currently, patients who undergo coronary artery bypass grafts remain in the hospital for around a 
week; the patients spend up to three days in the intensive care unit.
14
 The procedure will become 
less invasive and thus is expected to be more preferred by patients, by eliminating secondary 
surgeries to harvest grafts.
 
Surgeons 
 
 According to the Texas Heart Institute at St. Luke’s Episcopal Hospital, there were over 
450,000 coronary bypass procedures in 2006 alone.
15
 Cardiac surgeons perform surgeries related 
to the heart, including both its vessels and arteries. Following successful approval for clinical use 
Patients
Surgeons
Research Practitioners 
and Doctors
Biomedical Engineers
WPI
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by the FDA, TEBVs would likely become a safe and effective alternative to the current coronary 
artery bypass surgical procedure.  
 In a news release by the American Heart Association, it is stated that up to 40% of 
patients receiving coronary artery bypass surgery do not have suitable vessels or arteries for graft 
procedures. As a substitute, these patients receive synthetic grafts. One main problem with these 
synthetic grafts is that they can cause severe infections and only 20% remain patent within 3 
years post surgery.
9
 By adding the option of using the TEBVs produced by the WPI device, 
surgeons will have another graft to use as an alternative to autografts and synthetic grafts. 
Research Practitioners and Doctors 
 
 Research practitioners are the most likely users of the kit produced by WPI. In a study 
performed by the Foundation for Biomedical Research, over 17 million animals are used each 
year in the United States for research purposes. This number has caused a number of political 
campaigns regarding animal cruelty and rights.
16
 Although there are a number of claims stating 
that the animals feel no pain during testing, there are still debates campaigning against animal 
testing as a preferred method to test new drugs and disease treatments. In a study done during the 
year 2000, it was found that there over $45 million was spent in biomedical research testing. It is 
the hope of the project team that the TEBVs produced from the WPI kit will be a valuable 
research alternative to animal testing. Should the technology work as expected, a small 
percentage of the animal research market ($45 million in 2000)
17
 can be for biomedical research 
testing for the project team to infiltrate. It is noted that most cardiovascular research, and more 
importantly research to test treatment alternatives for CABG procedures, is performed on canines 
because their respiratory system is similar to that of humans.
18 
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Biomedical Engineers 
 
 Biomedical engineers will benefit greatly from the expansion of the medical device 
industry. According to the United States Bureau of Labor Statistics, there are over 3,400 
biomedical engineers working within the medical equipment and supplies industry. This is the 
highest concentration of the nearly 15,000 employed biomedical engineers in any of the 
biomedical industries.
19
 Assuming that the technology will work to its desired functions, the 
author is confident that the product and technology will help advance the field and research 
performed by biomedical engineers The result may be more job opportunities for BMEs within 
the field. 
Worcester Polytechnic Institute and Inventors 
 
 Worcester Polytechnic Institute and the inventors of the TEBV producing device are the 
final stakeholders of the product. The institution currently has an invention disclosure on the 
product and process. This is essential to the WPI TEBV producing method because it is the 
beginning stages of protection for the technology. There is also another patent application 
describing the method and technology used to produce TEBVs; however, a full patent has not yet 
been issued. 
4.3.2 Cost Analysis of TEBV Device/Kit 
 
 The cost of the TEBV producing kit, created by members of the Worcester Polytechnic 
Institute biomedical department, will rely heavily on the company’s ability to successfully 
combine outsourcing with in-house production. It is important to understand the costs associated 
with producing and selling the kits as they are essential in the long-term business plan. The 
production of the kit includes the use of both machines and materials. To produce the kit, one 
will need a lathe for cutting the polycarbonate spinning cylinders to shape. Also, a CNC machine 
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is needed to produce the mold (either prototype or permanent) for the motor unit encasing. This 
section outlines the different potential scenarios regarding the production costs of the kit. Figure 
10 highlights the components contained within the case as well as the parts that need machining. 
 
Figure 10: Kit Components and Machined Parts 
 
Completely In-House Production 
 
 There are a number of costs associated with manufacturing the kit entirely in-house. 
Completely in-house production includes purchasing the materials, a lathe, and a CNC machine, 
along with hiring a mechanical engineer to operate the machinery, manufacturing all components 
in-house, and assembling the kit. During an interview with Randy Guertin
20
, the tool and 
engineering manager for Applied Plastic Technology in Worcester, Massachusetts, the costs of 
the required machines was discussed. The following costs associated with completely in-house 
production are seen in Table 1 below. 
 
 
 
 
 
Parts Within Kit
• Motor and encasing
• Polycarbonate spinning cylinders
• Syringe
• Bioreactor 
• User manual
Machined Parts
• Motor encasing 
• Polycarbonate spinning cylinders
• Mold
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Costs (Completely In House)     Number of Units Produced     
    10 30 50 100 250 500 
Lathe Cost   $10,000 $10,000 $10,000 $10,000 $10,000 $10,000 
CNC Machine Cost (Used)   $25,000.00 $25,000.00 $25,000.00 $25,000.00 $25,000.00 $25,000.00 
Prototype Mold (used in CNC machine)   $5,500.00 $5,500.00 $5,500.00 $5,500.00 $5,500.00 $5,500.00 
Material Costs for Motor House Unit   $50.00 $150.00 $250.00 $500.00 $1,250.00 $2,500.00 
Mechanical Engineer Labor Cost (per hr)   $38.74 $38.74 $38.74 $38.74 $38.74 $38.74 
Cost of Polycarbonate Rods (10 units)   $266.00 $798.00 $1,330.00 $2,660.00 $6,650.00 $13,300.00 
Total Cost   $40,816 $41,448 $42,080 $43,660 $48,400 $56,300 
Total Cost per Unit    $4,081.60 $1,381.60 $841.60 $436.60 $193.60 $112.60 
Table 1: Completely In-House Production Cost Analysis.  *Median Mechanical Engineer Salary.21 
  
 The first machine needed in the production of the kit is a basic lathe for the 
manufacturing of the polycarbonate cylinders. Guertin indicated that the cost of an appropriate 
lathe would be $10,000. The production team would also need to purchase a CNC machine, 
which is used in forming the plastic motor housing, a cost of $100,000 new or $25,000 used. 
Finally, the production team would need to purchase a mold (either prototype or permanent) that 
would be used within the CNC machine to produce the plastic motor housing. For the purpose of 
this analysis, a prototype mold ($5,500.00) was used, because the production team would likely 
want to test the design first with the prototype mold in order to fix any imperfections with the 
design. Once the design is perfected, it would then be worth purchasing a permanent mold which 
can withstand long-term production use. The cost associated with the materials for the motor 
housing units is around $5.00 per unit.
20
  
 It is equally important to recognize the cost of hiring a mechanical engineer to run the 
production of the kit. Also, the mechanical engineer brings the expertise of drawing the product 
on computer design software (such as AutoCAD) and thus would be able to complete many of 
the required processes. The United States Department of Labor states that the median hourly 
wage for a mechanical engineer is $38.74 per year. The total cost per kit, if 500 kits are 
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manufactured completely in-house, is $112.60 per unit. The mechanical engineer was used as the 
main engineer to run the production of the kit because he/she has both expertise with the 
machinery and how to complete the required processes.  
Completely Outsourced Production 
 
 When outsourcing the production of the WPI kit, the costs of manufacturing a mold, the 
materials, and the labor for assembly must be taken into consideration. To successfully 
manufacture and assemble the kit, the manufacturing company would first need to design and 
fabricate a mold to be used for forming the plastic encasing for the hobby motor. There are two 
types of molds available for purchase through most manufacturing companies. Prototype molds, 
the less expensive of the two, cost anywhere from $5,000-$6,000 per mold. For the WPI kit, 
Randy estimated the mold to be around $5,500.  
 The prototype mold is a perfect option for clients that expect to produce less than 500 
units as the mold can only withstand the production of about 500 units.
20
 Once the prototype 
mold is purchased, each unit including the material and machining costs will be $3.00 per unit. 
Although the goal of the WPI project team is to produce around 25-30 units to first start a lease 
program, it is expected that long-term goals of the company would include manufacturing more 
than 500 units.
20
A cost analysis of the prototype mold for production of 10, 30, 50, 100, 250, and 
500 units is show below  (Table 2). Randy expected to be capable of machining 10 
polycarbonate cylinders per hour making labor costs of $2.50 per unit. The material cost for the 
cylinders is $0.16 per unit. If a prototype mold is used, the total cost per kit, if 500 kits are 
manufactured, is $45.60 per unit. 
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Costs (Prototype Molding)     NUMBER OF UNITS PRODUCED 
    10 30 50 100 250 500 
Prototype Mold Cost   $5,500  $5,500  $5,500  $5,500  $5,500  $5,500  
Unit Cost   $30.00  $90.00  $150.00  $300.00  $750.00  $1,500.00  
Assembly Labor Cost ($5 per unit)   $50.00 $150.00 $250.00 $500.00 $1,250.00 $2,500.00 
Cost of Polycarbonate Rods (10 units)   $266.00  $798.00  $1,330.00  $2,660.00  $6,650.00  $13,300.00  
Total Cost   $5,846  $6,538  $7,230  $8,960  $14,150  $22,800  
Total Cost (per Unit)   $584.60  $217.93  $144.60  $89.60  $56.60  $45.60  
Table 2: Completely Outsourced Production Cost Analysis for Prototype Mold 
  
 
 The second of the two molds is called a permanent production mold. This mold is 
fabricated mainly from steel and can withstand long-term production. Permanent production 
molds cost between $18,000 and $22,000. Again, Randy estimated that the total cost of a 
permanent mold for the WPI design would be $20,000. It is important to note that by purchasing 
the permanent mold, the company would then become the owner of that mold and thus could 
take it to another manufacturing company if that became the most suitable option.  
 Once the mold is purchased, the individual unit price of the encased motor units 
including materials and machining costs would be $2.00. Applied Plastic Technology can also 
assemble the units at an additional labor rate of $25.00 per hour. Mr. Guertin expected that his 
crew would be capable of assembling five of the encased motor units per hour making the cost of 
assembly an additional $5.00 per unit.
20
 This additional $5.00 per unit is the associated labor cost 
should the production be completely outsourced. A cost analysis of the permanent mold for 
production of 10, 30, 50, 100, 250, and 500 units is show below in Table 3. The table also 
includes the cost of a 10 piece starter pack of polycarbonate cylinders. If the permanent mold is 
used, the total cost per kit, if 500 kits are manufactured, would be $73.60 per unit. 
 
 
42 
 
Costs (Permanent Molding)  
 
  NUMBER OF UNITS PRODUCED   
    10 30 50 100 250 500 
Permanent Mold Cost   $20,000  $20,000  $20,000  $20,000  $20,000  $20,000  
Unit Cost   $20.00  $60.00  $100.00  $200.00  $500.00  $1,000.00  
Assembly Labor Cost ($5 per unit)   $50.00 $150.00 $250.00 $500.00 $1,250.00 $2,500.00 
Cost of Polycarbonate Rods (100 units)   $266.00  $798.00  $1,330.00  $2,660.00  $6,650.00  $13,300.00  
Total Cost   $20,336  $21,008  $21,680  $23,360  $28,400  $36,800  
Total Cost per Unit   $2,033.60  $700.27  $433.60  $233.60  $113.60  $73.60  
Table 3: Completely Outsourced Production Cost Analysis for Permanent Mold 
 
Mixed Production Scenarios 
 
 To help reduce the costs associated with manufacturing, the author has developed a 
scenario for producing the WPI kit including both in-house and outsourced manufacturing. This 
scenario includes having the lathing of materials outsourced, component manufacturing 
outsourced, and assembly of the units in-house. The author decided that it would be beneficial 
for the company to first purchase a prototype mold. The reason for this is to ensure that the 
design is tailored to the customers need. By utilizing the lease program outlined in section 4.2.7, 
the company will be able to receive feedback from the customers/users thus allowing them to 
make any modifications needed to maximize the function of the products. Once these design 
changes are made, the company would then be advised to purchase a permanent mold for long-
term production. By outsourcing the production aspect of the process, the company could 
eliminate the need of a mechanical engineer to run the machinery.  
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Costs (Prototype Molding) 
Mixed Production 
    NUMBER OF UNITS PRODUCED 
    10 30 50 100 250 500 
Prototype Mold Cost   $5,500  $5,500  $5,500  $5,500  $5,500  $5,500  
Unit Cost   $30.00  $90.00  $150.00  $300.00  $750.00  $1,500.00  
In-House Assembly Labor Cost ($2.64 
per unit) 
  $26.40 $79.20 $132.00 $264.00 $660.00 $1,320.00 
Cost of Polycarbonate Rods (10 units)   $266.00  $798.00  $1,330.00  $2,660.00  $6,650.00  $13,300.00  
Total Cost   $5,822  $6,467  $7,112  $8,724  $13,560  $21,620  
Total Cost (per Unit)   $582.24  $215.57  $142.24  $87.24  $54.24  $43.24  
Table 4: Mixed Production Cost Analysis. 
 As seen in Table 4, the row highlighted in green shows the in-house assembly costs. All 
other costs associated with the production are outsourced in this mixed scenario. Of the 
aforementioned scenarios, the mixed production scenario produces the lowest cost per kit if 500 
units are manufactured at $43.24 per kit.  
4.3.3 Cost Analysis of Tissue Engineered Blood Vessels from WPI Kit 
  
 The following section highlights the costs associated with producing TEBVs for human 
clinical use. The approval process of the USFDA is also examined. 
United States Food and Drug Administration Certification 
 
 The United States Food and Drug Administration (FDA) is responsible for regulating and 
certifying all food and drug products for sale in the market place. The Center for Biologics 
Evaluation and Research (CBER) is a subdivision of the FDA responsible for regulating and 
certifying new biological treatments introduced to the market. To obtain approval through the 
FDA and the CBER, the company must first contact the FDA with specific information 
regarding the proposed application of the product as well as the positive effects as well as 
negative effects the product will cause. Once having notified the FDA with the aforementioned 
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information, the TBEVs must be tested on animals and in laboratories by research scientists to 
provide clinical performance data to the FDA.
23,24
  
 Once clinical data is obtained, the company would then file for an application for 
exemption through the FDA known as an investigational new drug (IND) application. This 
exemption allows the company to then test on human subjects. This study must be approved by 
the FDAs board of scientific and medical advisors. This board also consists of consumers within 
the proposed market. After performing thorough testing on the product, the company will supply 
the FDA with data proving the long-term patency regarding in-vivo use. Once the company can 
prove that the product is safe and provides valuable applications and results when used in 
humans, the FDA will certify the product thus making it market ready. According to the FDA 
website, a new drug application (NDA) typically takes 10 months to acquire. 
23,24 
Cost Analysis of Tissue Engineered Blood Vessels 
 
 The kit produced at WPI serves many applications including both research and the 
potential one day to produce a TEBV that can be used for clinical applications. There are many 
costs that must be considered regarding the production and culturing of cell-based grafts for 
clinical use. For the purpose of this study, the author proposed a four phase production method to 
breakdown the cost analysis of a TEBV. These costs can be correlated to the proposed four 
phases of production needed to create one TEBV. Phase 1 of the process is the phase in which an 
initial skin biopsy is obtained. This skin biopsy is used for harvesting the necessary living cells 
needed to produce a TEBV. Phase 2, the “front-end processing phase,” is where the cells from 
the skin biopsy are obtained and cultured for a 3 week period to prepare them for the spinning 
phase. Phase 3 is the spinning phase in which the cultured cells are placed into the WPI device. 
The spinning phase is the phase in which the cells are spun within the polycarbonate cylinder. 
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Finally, Phase 4 is the stage in which the TEBV is cultured and matured for clinical application 
(Figure 11).    
 
 
Figure 11: TEBV Production 4 Stage Process 
 
 The cost of the skin biopsy taken to provide dermal fibroblasts used in producing the 
tissue engineered blood vessels must be considered. Also, the cost to ship a skin biopsy is taken 
into consideration. Next, the cost of the employees needed to produce the vessel through the 
latter three phases is examined. For the purpose of this analysis, it was assumed that the 
employees needed to produce the vessels would include two biomedical engineers and a 
medical/clinical laboratory technician. The biomedical engineers would be capable of 
performing any tasks related to the TEBVs and cell cultures. The laboratory technician would 
work directly with the biomedical engineers in ensuring that each TEBV produced is suitable for 
clinical applications. The technicians would also carry out any needed tasks requested by the 
biomedical engineers. In the following paragraph, the hourly wage rates of the aforementioned 
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professionals are discussed. Finally, the cost of materials such as cell media used to feed the 
cells/TEBVs is examined.  
 Using data from the U.S. Department of Labor regarding the average salary of a 
biomedical engineer, it was determined that the mean hourly wage is $39.69.
25
  Using similar 
data, it was determined that the mean hourly wage for a medical/clinical laboratory technician is 
$18.20.
26
  
 
Phase 1 
 
 Phase 1 of the TEBV production process is where the skin biopsy is obtained. The skin 
biopsy is essential in the process in that dermal fibroblasts are extracted and used to produce the 
TEBV. The overall time for this process is the shortest of the four phases. The skin biopsies must 
be shipped to the facility where they will be grown into sheets and cultured. According to Todd 
McAllister et al., it was stated that the mean transport time for the cell cultures was 26.7 hours.
27
 
This is important because it is expensive to transport living cell cultures (Table 6).  
 The cost of 21,692 individual skin biopsies in the state of Florida during the 2009 
calendar year was examined. The study conveyed the number of skin biopsies for each hospital 
in the state as well as the low and high cost of each procedure. The average low cost (associated 
with punch biopsies), average high cost (associated with surgical biopsies), and the average cost 
of skin biopsies is shown below (Table 5).
 28 
 
Biopsy Cost  
Low High Average 
$2,247  $8,876  $5,562  
Table 5: Average low, high, and overall average cost of a skin biopsy in Florida hospitals during the 2009 calendar year.28 
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 The average cost to transport living tissues was found through FedEx overnight next 
morning delivery shipping is $48.55 for a 3 pound package and $50.65 for a 5 pound package. 
The average of these two shipping costs is $49.60. An additional cost of $25 is added due to the 
transportation of “hazardous material.” This makes the total shipping cost $74.60 for a skin 
biopsy. The total cost of the biopsy ($5,562) plus the total shipping cost ($74.60) are added for a 
total $5636.60 for phase 1 of the TEBV production. 
 
Materials: Costs: 
Cell Biopsy $5,562  
Transportation (overnight) $74.60 
Total Cost: $5,636.60 
Table 6: Phase 1 Cost Analysis 
 
Phase 2 
 
 Phase 2 of the process is considered the “front-end processing phase.”  During this phase, 
the dermal fibroblasts extracted from the skin biopsies are cultured in order to prepare them for 
use in the WPI device (kit) noted in Phase 3. There are both labor and material costs associated 
with this phase. Both biomedical engineers and the technician will be involved in the final three   
phases of TEBV production. These workers are needed to feed the cells media and to monitor the 
growth of the cultured fibroblasts. In a 2006 Nature Medicine journal article, Nicolas L’Heureux 
of Cytograft stated that this phase takes around six weeks to complete. It is also stated that during 
this time, the cells are fed media that changes three times weekly. Conversely, Phase 2 of the 
process at WPI has been reduced to just three weeks. There are two segments to the three week 
phase. The first is a two week front-end processing segment in which the two million dermal 
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fibroblasts are extracted from the skin biopsy. The second segment is a one week phase in which 
the cells are doubled until the target of 100 million cells needed to produce a TEBV is reached. 
 During Phase 2, the goal is to grow 100 million cells from an initial two million cell 
culture. The initial two million cells will be split amongst three flasks. It was decided through a 
personal communication with biomedical engineering professor Marsha Rolle that the doubling 
time for the dermal fibroblasts should be approximately 24 hours. Also, every two days, the 
flasks used to house the cell cultures must be split into three new flasks to allow room for the 
cells to grow. An example of this doubling process can be seen below in Figure 12. Also, Table 7 
conveys the number of days, number of cells, and number of flasks it takes to reach the target of 
100 million cells.  
 
Day # of Cells 
(millions) 
# of 
Flasks 
1 2 3 
2 4 3 
3 8 9 
4 16 9 
5 32 27 
6 64 27 
7 128 Harvest 
Table 7: Cell Doubling Data 
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Figure 12: Cell Doubling Flask and Time Example 
 During a personal communication on January 10, 2011 with Craig Jones, a biomedical 
engineering student who worked on the 2009/2010 WPI MQP related to this analysis, the time 
associated with preparing and administering cell media was determined. Jones stated that it takes 
about 15 minutes to prepare the media and administer it to the cells per dish.
29
 Hence, during the 
3 week phase and 87 media cycles (six cycles in weeks one and two/81 cycles over 27 flasks in 
week 3), it is determined that the total labor time for this phase is 1,305 minutes (21.75 hours).  
 During the three week Phase 2, the cell media is changed weekly to help the cells grow 
and mature. This frequent changing of the media, however, increases the cost to produce one 
vessel. The cell media used in the Cytograft process will be used as the model when examining 
the costs associated with the WPI process. Cytograft currently uses a media composed of 
Dulbecco’s modified eagles medium (DMEM). This media is supplemented with Ham’s F12 
(20%) which contains streptomycin and penicillin, and FetalClone bovine serum (20%). The 
total volume of each media exchange is 45mL. By purchasing the cell media ingredients through 
the online company Sigma Aldrich, the author has concluded that a 10 liter bottle of Dulbecco’s 
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modified eagles medium costs $32.30. Similarly, a 500mL bottle of Ham’s F12 costs $23.50, and 
a 500mL bottle of FetalClone bovine serum costs $128.82. A cost analysis of the required 
amount of media as well as the total cost for three weeks of media exchanges (3 weeks x 3 
exchanges per week (per flask)) plus the included labor for phase 2 is examined in Table 8. 
 
Cost Factor   
Labor: Cost 
Biomedical Engineer (2) ($39.69/hr) $1,726.52 
Laboratory Technician ($18.20/hr) $386.75 
    
Materials:   
Media (87 exchanges= $2.89 * 87) $251.43 
    
Total Cost of Phase 2 $2,364.70 
Table 8: Phase 2 Cost Analysis 
Phase 3 
 
 Phase 3 of the WPI TEBV production process is the stage in which the WPI device used 
for spinning the cells is implemented. This phase is where the WPI process differs from that of 
Cytograft’s and is likely to be the phase in which WPI can reduce the total production time. 
Phase 3 takes roughly three days to complete. Currently, as previously stated, Cytograft uses 
three exchanges of media weekly. Due to the media cycle discussed in L’Heureux’s papers, it is 
assumed that this stage will only need one exchange of media since it will be completed in only 
three days; however, based on the original cell count versus the new cell count, media will need 
to be continually administered throughout the three days thus using one media cycle per day. 
 The total cost of this phase includes the labor rate for the two biomedical engineers and 
the technician. The biomedical engineer will be used to control the entire process. The technician 
will be used to assist the biomedical engineer in any processes that need to be completed. 
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Finally, the engineers and technician will test each vessel produced during this phase for quality 
control purposes.  
 It is important to note that although this phase takes three days to complete, engineers 
will likely be working on this phase of vessel production for a total of only one hour and forty-
five minutes (3 media cycles for 15 minutes each and another hour for inserting the cells and 
removing them from the tube). This is because the cells will be placed into the device, spun for 
15 minutes, and then allowed to incubate for the remainder of the three days. The cost analysis of 
this phase also includes the cost of one exchange of media. A cost analysis for phase 3 can be 
seen in Table 9. 
 
Labor: Cost 
Biomedical Engineer (2) ($39.69/hr)  $128.42  
Laboratory Technician ($18.20/hr) $31.85 
    
Materials: Cost 
Media (3 exchanges) $8.67  
    
Total cost of Phase 3 Production $168.94  
Table 9: Phase 3 Cost Analysis 
 
Phase 4 
 
 Phase 4 of the WPI TEBV production process is similar to the fourth phase of Cytograft’s 
TEBV production process. During phase 4, the TEBV is removed from the spinning device and 
allowed to mature over a minimum of 10 weeks. Over the 10 week period, there will be a total of 
30 media cycles. With each media cycle taking 15 minutes to administer, the total labor time for 
this phase will be 450 minutes (7.5 hours).  
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 The total labor time used in calculating the cost of phase 4 will be 10 hours through the 
assumption that there may be alternative labor needed during this phase. This labor could include 
frequent quality control checks by the biomedical engineers and laboratory technician and basic 
tasks performed by the laboratory technician to maintain tissue maturation. As Table 10 conveys, 
the two staff members of this phase include the biomedical engineer and the laboratory 
technician.
 
 
 
Cost Factor   
Labor: Cost 
Biomedical Engineer (2) ($39.69/hr) $793.80 
Laboratory Technician ($18.20/hr) $180.20 
  
Materials:   
Media (1 exchange= $2.89 * 30) $86.70 
    
Total Cost of Phase 4 $1,060.70 
Table 10: Phase 4 Cost Analysis 
  
Total Costs 
 
 The total cost of one tissue engineered blood vessel is calculated by adding the costs 
associated with each of the four phases of production. Table 11 examines the summation of costs 
for the four phases. The author assumes that this cost can be considered accurate in that the 
estimated time values used in calculating labor costs are accurate and based on both Cytograft’s 
and WPI’s current production methods. The cost of media was examined by using the online 
biomedical supplies distributor Sigma Aldrich. 
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Phase Cost 
    
Phase 1 $5,636.60  
Phase 2 $2,364.70  
Phase 3 $168.94  
Phase 4 $1,060.70  
    
Total Cost to produce one TEBV: $9,230.94 
Table 11: Total Cost to Produce One TEBV- Phase Summation 
 
 
 
 
4.3.5 Economic Factors of TEBVs 
 
 The TEBVs produced using the process at WPI will likely have limited direct 
competition in the market as outline in section 4.4.2. Due to the current limit of competition 
within the industry and the assumption that WPI’s TEBVs become the industry choice for 
CABG, WPI will have an easy market to control. This will be especially true if the product is 
able to surpass the competing products in both design and function. The product is also likely to 
succeed due to its ability to have alternative applications for clinical use. For example, the 
TEBVs could be used to replace damaged or destroyed vessels or arteries in other parts of the 
human body other than being used strictly for coronary artery bypass surgery. 
 The supply and demand are important factors to consider when bringing a new product to 
market. The elasticity of the product is also an important factor to consider. Patients, the end-
users of the product, are likely to find the cost of this product relatively inelastic. This means that 
the product is necessary for the patient and therefore the patient is likely to choose this product 
regardless of the price, even though most of the cost is borne by a third-party insurance 
company.    
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 In Figure 13 below, the supply and demand curves are examined for the TEBVs produced 
by WPI. The following figure shows an example of how the supply and demand will change 
should the product experience sales success in the market. The supply and demand curves and 
their movements are based on the standard supply and demand model of a successful product. It 
should be noted that the demand curve moves to the right due to the benefit that the TEBVs bring 
to the market place. As the products demand raises over time, the company started by WPI 
inventors will likely streamline the production process to adequately supply the market with 
TEBVs by increasing the efficiency of the manufacturing process. This increase in efficiency is 
likely to cause the supply curve to move right as more units will be produced through the more 
streamlined production method.   
 
 
 
         Price (y) 
      D1                         D2 
 
 
 
 
               Cost 
 
 
 
 
      S1                           S2 
 
      Quantity (x) 
 
Figure 13: Supply and Demand Curves for WPI's TEBVs 
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4.3.6 Break-even Analysis 
 
 A break-even analysis is used to determine how many units must be sold in order for a 
company to break-even and thus begin generating a positive net income, without regard to time.   
WPI Kit Break-Even Analysis 
 
 The following section outlines the break-even analysis for the TEBV producing kit 
manufactured by WPI. For the purpose of this analysis, the cost of $215.57 per kit (Table 4), will 
be approximated at $220.00 per kit. This number was chosen because it was mentioned that the 
project team would first attempt to produce 30 kits for sale. First Research, a database provided 
by WPI in which industry statistics are examined for each industry in the U.S. market, states that 
the average margin for products in the medical supplies and devices industry is between 40%-
60%.
30
 For the purpose of this analysis, we will assume that the WPI kit will have a margin on 
the lower end of this spectrum. This was done to ensure that the break-even analysis cover the 
bare minimum of necessary sales to break-even.  This was done to ensure that the production 
team would know the maximum number of units that needed to be sold in order to break-even. 
The margin was set at 45% so that the selling price of each kit would be $320. In Table 12, 
shown below, the break-even point for the WPI device is examined. Appendix 8.3 examines a 
chart of this data. 
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BREAK-EVEN ANALYSIS FOR WPI KIT  
Number of 
Units 
Produced and 
Sold 
Fixed Cost 
(mold) 
Total Cost ($45 per 
unit) 
Total Revenue Net Profit 
0 $5,500.00 $5,500.00 $0.00 -$5,500.00 
1 $5,500.00 $5,545.00 $320.00 -$5,225.00 
2 $5,500.00 $5,590.00 $640.00 -$4,950.00 
3 $5,500.00 $5,635.00 $960.00 -$4,675.00 
4 $5,500.00 $5,680.00 $1,280.00 -$4,400.00 
5 $5,500.00 $5,725.00 $1,600.00 -$4,125.00 
6 $5,500.00 $5,770.00 $1,920.00 -$3,850.00 
7 $5,500.00 $5,815.00 $2,240.00 -$3,575.00 
8 $5,500.00 $5,860.00 $2,560.00 -$3,300.00 
9 $5,500.00 $5,905.00 $2,880.00 -$3,025.00 
10 $5,500.00 $5,950.00 $3,200.00 -$2,750.00 
11 $5,500.00 $5,995.00 $3,520.00 -$2,475.00 
12 $5,500.00 $6,040.00 $3,840.00 -$2,200.00 
13 $5,500.00 $6,085.00 $4,160.00 -$1,925.00 
14 $5,500.00 $6,130.00 $4,480.00 -$1,650.00 
15 $5,500.00 $6,175.00 $4,800.00 -$1,375.00 
16 $5,500.00 $6,220.00 $5,120.00 -$1,100.00 
17 $5,500.00 $6,265.00 $5,440.00 -$825.00 
18 $5,500.00 $6,310.00 $5,760.00 -$550.00 
19 $5,500.00 $6,355.00 $6,080.00 -$275.00 
20 $5,500.00 $6,400.00 $6,400.00 $0.00 
Table 12: Break-Even Analysis for WPI Kit 
 
 In Table 12, there are four major categories regarding the manufacturing of the WPI kit. 
The fixed cost of $5,500.00 is for the prototype mold that will be used to produce the first 30 
kits. The calculations in Table 12 were done by using the formula TVC= FC+VUC*n/n. This 
formula is for the total variable cost and considers the fixed costs, variable unit costs, and the 
number of units produced. As seen in the table, the WPI kit would have a relatively short 
payback period of only 20 units. This means that once the company has purchased the prototype 
mold and sold 20 of the kits, the company would then begin generating a net profit from the 
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units. A break-even analysis does not include the cost of labor; it merely takes into account the 
fixed costs and unit costs associated with a product as well as the selling price. 
WPI Tissue Engineered Blood Vessels Break-Even Analysis 
  
 This section examines the break-even analysis for the production of WPI’s tissue 
engineered blood vessels. As previously stated, First Research database lists that the average 
margin for products sold in the medical supplies and devices industry is between 40%-60%. 
When calculating the margin on the WPI kit, it was assumed that it would be on the lower 
spectrum of this range due to the mechanical nature of the product. When deciding the percent 
margin for the WPI TEBVs, due to the nature of the product and the fact that no product 
currently exists in the market with the same applications, the author assumed that the product 
would receive the higher end of the margin range at 60%.  
 As seen in Table 13 below, the examined values are the initial investment of $100,000, 
the total cost per TEBV plus the initial investment, the total revenue, and the net profit. The 
author set the initial investment at $100,000 to test the payback period for potential investors. 
This is a standard investment by angel investors to start-up firms. Angel investors are people 
who supply firms with capital. The total TEBV cost was calculated by adding the initial 
investment to the cost of one TEBV. The cost of the TEBV was multiplied by the number of 
units produced. The total revenue for the TEBVs was calculated by multiplying the total cost of 
the TEBV by the 60% margin and then by adding the margin to the cost to produce one TEBV. 
As seen in Table 13 regarding the cost analysis of TEBVs, it costs about $10,000 to produce one 
TEBV. The revenue associated with one TEBV was calculated to be $16,000. Finally, the net 
profit was calculated by subtracting the total costs from the total revenue. It was found through 
this analysis that with an initial investment of $100,000, the break-even point for the sale of 
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WPIs TEBVs is at 17 units. Table 13 below examines the break-even analysis for WPIs TEBVs 
with an initial investment of $100,000. It can be seen that with an initial investment of $100,000, 
investors can expect a positive return on investment (ROI) at 17 units sold with a total net profit 
of $2,000.  Appendix 8.4 examines a chart of this data. 
 
BREAK-EVEN ANALYSIS FOR WPI TEBVs  
Number of 
Units 
Produced 
Fixed Cost 
(Investment) 
Total Cost (Labor+ 
Materials) 
Total Revenue Net Profit 
0 $100,000.00 $100,000.00 $0.00  $ (100,000.00) 
1 $100,000.00 $110,000.00 $16,000.00  $    (94,000.00) 
2 $100,000.00 $120,000.00 $32,000.00  $    (88,000.00) 
3 $100,000.00 $130,000.00 $48,000.00  $    (82,000.00) 
4 $100,000.00 $140,000.00 $64,000.00  $    (76,000.00) 
5 $100,000.00 $150,000.00 $80,000.00  $    (70,000.00) 
6 $100,000.00 $160,000.00 $96,000.00  $    (64,000.00) 
7 $100,000.00 $170,000.00 $112,000.00  $    (58,000.00) 
8 $100,000.00 $180,000.00 $128,000.00  $    (52,000.00) 
9 $100,000.00 $190,000.00 $144,000.00  $    (46,000.00) 
10 $100,000.00 $200,000.00 $160,000.00  $    (40,000.00) 
11 $100,000.00 $210,000.00 $176,000.00  $    (34,000.00) 
12 $100,000.00 $220,000.00 $192,000.00  $    (28,000.00) 
13 $100,000.00 $230,000.00 $208,000.00  $    (22,000.00) 
14 $100,000.00 $240,000.00 $224,000.00  $    (16,000.00) 
15 $100,000.00 $250,000.00 $240,000.00  $    (10,000.00) 
16 $100,000.00 $260,000.00 $256,000.00  $      (4,000.00) 
17 $100,000.00 $270,000.00 $272,000.00  $        2,000.00  
18 $100,000.00 $280,000.00 $288,000.00  $        8,000.00  
19 $100,000.00 $290,000.00 $304,000.00  $      14,000.00  
20 $100,000.00 $300,000.00 $320,000.00  $      20,000.00  
 
Table 13: Break-Even Analysis for WPI TEBVs. 
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4.3.7 SWOT Analysis (Strengths, Weakness, Opportunities, Threats) 
 
 A SWOT analysis is used to determine the strengths, weaknesses, opportunities, and 
threats of any given product. It is useful in that it helps a company better understand that benefits 
of their product versus the negative aspects. The strengths are the features that make the product 
valuable to the end-user. The weaknesses are the limitations that may be a detriment to the 
overall function of the product. The opportunities section covers the business opportunities that a 
business may experience if they were to sell the proposed product. Finally, the threats section is 
used to better understand the threats to the products success, such as competitors within the 
target market. A SWOT analysis was performed for the TEBVs produced through the means of 
the WPI technology and method. (Figure 14). 
Strengths Weaknesses (Early in experimental 
stage) 
 Made from living cell cultures thus having 
similar mechanical properties as native 
tissues 
 Treats cardiovascular disease and may help 
prevent future occurrences  
 Can take cell culture from patients to 
generate autologous tissue 
 New and unique; Entering market with 
growth potential 
 Will improve the overall quality of a 
patient’s life 
 Currently, WPI is unable to control the 
process 
o Many unknown variables  
 Vessels not always uniform in structure 
o Vessel may not be uniformly 
strong 
Opportunities Threats 
 Need for alternative method to current 
treatment of cardiovascular disease. 
 Competitors process not as time efficient as 
WPI’s process 
 Biomedical market is growing 
exponentially 
 Future applications outside cardiovascular 
disease treatment are possible.  
 
 FDA regulations continue to change and 
become more stringent 
 Insurance reimbursement and coding 
 Current lack in funding  
 Many unknowns; potential for future 
problems in production process  
 Reverse engineering of WPI device/kit and 
method 
Figure 14: SWOT Analysis for Tissue Engineered Blood Vessels Produced by WPI Technology and Method. 
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4.4 Market Position 
 
4.4.1Market Segmentation 
 
 Market segmentation is an analysis in which a business focuses on each of the potential 
buyers for a given product. It is important to understand these potential buyers and what factors 
may influence their decisions. The biomedical industry has a number of potential buyers due to 
the fact that TEBVs have many applications. The three most obvious potential buyers are 
pharmaceutical companies, doctors/hospitals, and research and university laboratories.    
 Pharmaceutical companies are promising potential buyers due to the current expansion of 
the pharmaceutical industry towards the biomedical and biotechnology industries. The 
pharmaceutical companies would most likely use this technology to perform tests on living 
cardiovascular tissues to test the safety and efficacy of the manufactured drug. The 
pharmaceutical industry is one of the largest industries in the market with four of its companies 
in the top 20 by market capitalization. 
 Doctors and hospitals would be the most important market segment to capture because it 
would help save lives; however, it would be the most difficult to capture. This segment would be 
responsible for the in vivo use of the TEBVs. Doctors would use the TEBVs during surgery to 
help cure patients of clogged arteries, cardiovascular diseases, etc. Although this market segment 
would be the most beneficial to the general population, it would be the most difficult to capture 
due to the stringent regulations set forth by the FDA.  
 Finally, the most realistic market segment is comprised of research laboratories and 
universities. The author feels that this segment is the most realistic in the short-term because the 
laboratories would not be using the TEBVs on living subjects. The laboratories would use the 
TEBVs for testing of all sorts including drug testing, disease testing, etc. The idea of creating a 
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kit for plug and play use would have appeal and value to these laboratories for a few reasons. 
First, the kit would eliminate extra training for scientists as they would receive a kit with specific 
directions on how to produce the TEBVs within their own labs. Also, the kit would eliminate the 
extra staff that the laboratory would need to hire to produce the TEBVs eliminating cost and 
allowing the labs to maximize profit.  
 Through the analysis of these market segments, the author has provided an in-depth 
analysis of the advantages and disadvantages of each segment. Also, an analysis of the 
stakeholders involved as well as a cost benefit analysis of the segments was performed to better 
understand each of the four segments. Finally, an analysis of the regulations and standards that 
would have to be met to sell to each of the four segments was crucial to understanding the costs 
associated with producing and selling the TEBV kits.  
4.4.2 Competition 
 
 One key component to analyzing a product’s target market is the current competition. A 
target market is the market in which the proposed company plans to sell the product. The 
Memorial Sloan-Kettering Cancer Center located in New York, New York holds a patent on an 
apparatus for growing cells under variable hydrostatic pressures (US Patent 7,435,587).
31
 In the 
patent, what is described to be a device that is enclosed and has at least one side set-up for “cell 
growth.” The device also has a means for administering and regulating the flow of cell media in 
order to feed the cells at a constant and/or continuous rate. The patent was filed on December 20, 
2004 and is currently owned by the Cancer Center. It is stated on the center’s website that the 
device and method has been tested with a cell study; however, efforts are still being made to 
fabricate and test the unit’s functionality.  The Cancer Center is a research facility and thus the 
technology is not actually being produced for sale; however, it is interesting to note that the 
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Cancer Center has a section on their website for “Technologies Available for Licensing,” where 
this apparatus can be found. It is dually noted that the device and its respective patent are not 
currently licensed to any individual or corporation. Due to its inactive status, this device would 
not be considered a competitor as it is not currently in production for sale at this time. It is 
important to note, however, that the patent could be licensed.  
  Cytograft, a company located in Novato, California, designed and patented (US Patent 
7,744,526)
32
 a device for manufacturing TEBVs. The device created by Cytograft performs a 
very similar function to the device created at WPI. The outcome of both devices is a tissue 
engineered blood vessel; however, Cytograft uses a rolling device to roll a sheet of cell tissue 
into a blood vessel where as the device created at WPI uses a machine to spin the cells thus 
allowing them to form the tube structure on their own. This phenomenon is not fully understood 
yet, but WPI is able to reduce the time to produce to about 13 weeks (as seen in section 4.3.3). 
The time to produce is much more efficient then Cytograft, which presently takes 24 weeks from 
the initial client meeting until the day the vessel is implanted into the patient. Although the 
Cytograft process takes a longer time, their product is currently in clinical trials giving them a 
clear advantage of market entry time. By having their product already in clinical trials, Cytograft 
will theoretically be able to enter the market prior to WPI and thus establish a client base long 
before WPI. Cytograft’s ability to produce a living tissue engineered blood vessel makes them a 
direct competitor to WPI’s TEBVs.  
 Organogenesis, INC., a company located in Canton, Massachusetts, designed and 
patented (US Patent 7,521,231)
33
 a method for preparing engineered tissues. The process defined 
in this patent is similar to that of Cytograft’s in that the company cultures cells and eventually 
fuses the cells into a sheet. Although Organogenesis, INC. does not currently produce TEBVs, 
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the patented technology is the first step in the process towards developing a method to produce 
TEBVs. Currently, the most similar product manufactured by Organogenesis, INC. is a product 
called Apligraft. Apligraft is a dual layered cell construct used in treating and curing venous leg 
ulcers. This was the first cell based product to receive FDA approval in 1998.  
 Finally, an article published in a recent issue of Science Translational Medicine, Laura 
Niklason and a group of engineers from the Yale Medical Group discovered a method for 
producing “readily available tissue-engineered vascular grafts.” With this method, the engineers 
were able to produce a vascular graft using human allogenic or canine smooth muscle cells.
34
 
The cutting edge aspect of these vascular grafts is that they do not consist of cellular material. 
During the process, all cellular material is eliminated by using detergents; making the grafts 
nonimmunogenic.
34
 This means that the grafts are unable to provoke an immune system 
response. During pre-clinical testing, the human grafts were tested in baboons and passed a 
number of tests including dilation tests, burst pressure tests, and suture pull tests. Canine grafts 
were put through similar functionality/patency tests in canine subjects and conveyed similar 
results. 
 The interesting aspect of this new method to producing tissue-engineered vascular grafts 
is the ability to produce them independent of cellular material. By producing grafts independent 
of cellular material, and greatly reducing the occurrence of immune rejection of the graft, this 
new technology must be considered as competition to the TEBVs produced at WPI. Although 
these grafts have potential benefits and are currently in clinical trials, the process still takes 
between three and six months.  
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4.4.3 Industry Analysis 
 
 There are a number of industries to consider when entering the market with a new 
biomedical device. The device and method invented at Worcester Polytechnic Institute (WPI) 
can fall into two separate industries, the manufactured pharmaceuticals and the medical supplies 
and devices industries. The method and device can be considered as part of the manufactured 
pharmaceuticals industry, which includes the sale of pharmaceutical drugs; however, the industry 
is beginning to expand by the addition of biomedical/biological products. The manufactured 
pharmaceutical market is driven by each company’s desire to cure and treat illness and disease.5 
The proposed use of the WPI’s TEBVs in this industry would be as test subjects for new drugs. 
The vessels would also be used in testing alternative treatments in relation to cardiovascular 
disease. It is interesting to note that the demand of the pharmaceutical industry is driven by the 
aforementioned factors because it leaves the industry open for expansion.  
 The second industry that would be relevant to the product designed at WPI is the medical 
supplies and devices industry. This industry is the most applicable in the event that WPIs device, 
the kit, is capable of producing a stable tissue engineered blood vessel for use in humans to treat 
cardiovascular disease. Once the vessels are tested to prove long-term patency, they would 
receive through the FDA. With this approval a company built through WPI to produce the 
TEBVs would be eligible to enter this market. Potentially, surgeons and doctors would purchase 
the TEBVs for use in treating cardiovascular disease in their patients. The demand is driven by 
different factors in the medical supplies and device industry. The medical supplies and device 
industry’s demand is driven by demographics.30 In regards to this demand, WPI has favorable 
population demographics as it is located in Worcester, MA, which is located in the vicinity of 
many highly regarded medical facilities. According to the U.S. News and World Report, 
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Massachusetts General Hospital (within a distance of 50 miles) is ranked within the top five 
hospitals in the world in 13/15 potential categories.  
 When analyzing the market, it is important to take an in depth look at each of the 
prospective entry industries. The pharmaceutical industry would be the most applicable for the 
device (kit), as well as the initial vessels designed and manufactured at WPI. The pharmaceutical 
industry is comprised of such companies as Johnson & Johnson, Pfizer, and Merck. First 
research states that, The US manufactured pharmaceuticals industry generates nearly $200 
billion annually amongst 1,500 companies.
35 
It is also noted that the industry is dominated by the 
upper 3% of the companies, which generate $160 billion of the annual $200 billion.  
 Over the past few years, the pharmaceutical market has expanded with the introduction of 
the biotechnology industry. Because the industry is dominated by larger companies, the smaller 
companies within the industry have a lot of competition. The difference between the large and 
small companies, however, is the demand is driven by different factors. It was noted that the 
demand is driven by the desire to cure illness in the larger companies. Inversely, the smaller 
companies demand is driven by their ability to produce specific products that can target one or 
two ailments.
36
 The smaller companies lack the ability to compete with larger and more 
established companies within the same market niche. In order to remain competitive, smaller 
companies need to target a specific niche that no larger company is targeting. The technology 
designed at WPI is specific and original enough to give the company a competitive edge in the 
expanding pharmaceutical market.  
 The latter of the two industries discussed is the medical supplies and device industry. 
This industry is the more practical choice for WPI should they design a kit for “plug and play” 
use by laboratories and doctors. The medical supplies and device industry is comprised of over 
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11,000 companies. Yet it generates about $125 billion less in revenue per year than the 
pharmaceutical industry. This is largely due to the fact that the pharmaceutical industry has a 
larger client base than the medical supplies and devices industry. Although the revenue stream is 
less than that of the pharmaceutical industry, it is important to note that in the 2010 calendar 
year, the medical supplies and devices industry had a growth rate of 9%, whereas, the 
pharmaceutical market had a growth rate of 6%.
30,35
 
 The medical supplies and devices industry is composed of companies such as Medtronic, 
Boston Scientific, and Johnson & Johnson. First Research is an online database supplied by WPI 
consisting market and industry analyses. First Research is published by Hoovers, which is a 
business research company. The website allows individuals to research a number of different 
aspects of each industry and the companies in which they include. In the analysis performed by 
First Research, in relation to the medical supplies and devices industry, the database claims that 
the technology invented at WPI is clearly specialized although it has many applications.
30 
 Following the analysis of the individual industries, the author concluded that the more 
appropriate industry for WPI to market plug and play kit would be the medical supplies and 
devices industry. The TEBVs can be marketed in manufactured pharmaceuticals industry. 
Although, initially, the company will focus on marketing the kit, the author believes that a 
company formed through WPI will be capable of competing in multiple industries. For example, 
Johnson & Johnson competes in both of the prospective markets that were analyzed in this 
report.
30 
 
 
 
67 
 
4.4.4 Marketing WPI TEBVs and Technology 
 
 The TEBV producing kit will likely be marketed to research facilities looking for a 
means to produce living tissue constructs that can be used for testing new drugs and disease 
treatments. It is essential that WPI can provide data to the research facilities proving that they 
will be a beneficial research tool in developing new drugs and treatments. There are two major 
identifiable benefits for researchers using the WPI kit, namely the ability to produce living 
tissues through a “do-it yourself” medium.  
 The first major benefit is the kit’s ability to produce a living tissue construct that can be 
used for a multitude of applications. The second major benefit of the kit is its ability to “do-it 
yourself.” It is the author’s recommendation to WPI that the product be marketed for its “do-it 
yourself” ability as this will be appealing to research facilities. By marketing this aspect of the 
product heavily, researchers will see the benefit of the product in that they will need no prior 
knowledge of the technology in order to produce living tissue constructs within their facilities. 
This stage of marketing is essential to the prospective company’s future. It will likely be the 
building block for future expansion of the company by generating the necessary revenue to be 
capable of producing and selling living TEBVs for use in humans to treat cardiovascular disease. 
 When marketing the TEBVs produced by WPI, the end-users of this product are the 
patients. It is important, however, to recognize that surgeons and doctors performing the 
procedures to treat cardiovascular disease are the consumers of the TEBVs and the actual 
decision-makers for the products. Surgeons and doctors will need to be convinced that the 
TEBVs produced at WPI are both safe and provide a valuable benefit to the patient that no other 
alternative treatment can provide. It is dually important that the treatment be approved by the 
FDA and coded by insurance companies. 
68 
 
  Ultimately, doctors choose which treatments they will use within their practice. It will be 
critical that the company is able to prove to doctors that the TEBVs provide a clinical and 
medical benefit to the patient and will also provide an economical benefit to the doctors. The 
doctors must understand that they will have a successful product for their patients. If WPI’s 
TEBVs do not perform better than the competition, then the medical benefits will need to 
outweigh the cost difference among alternatives. If the vessels are able to perform like native 
vessels, the author feels that it will be easy to convince surgeons of the TEBVs benefits.  
4.4.5 Benefits of Licensing Technology versus Starting a Company 
 
 One question that arises when performing a cost analysis on the TEBVs produced by 
WPI is whether it would be more beneficial to license the technology to a larger firm. Licensing 
intellectual property to a larger company is a common procedure for smaller companies/potential 
companies to generate revenue in a market that they likely could not infiltrate on their own. 
There are three different types of licensing that can be considered:  
 Lump sum licensing- A larger company purchases the rights of a smaller company’s 
intellectual property with a single payment.  
 Royalty based system- A larger company would pay a smaller company based on the 
volume of products sold.  
 Cross-licensing- Where the two companies license products to each other in a trade type 
manner.  
 
 The most applicable licensing scenario for the WPI TEBVs would be a sale volume based 
licensing agreement in which the larger firm would make payments to the WPI company based 
on the number of units the larger firm sells. According to William H. Black, many licenses are 
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set at a rate of 2-3% royalties.
37
 This means, for example, if a company were to license the WPI 
TEBVs and thus sell them for $5,000 per unit, then the royalties paid to WPI for the licensing 
agreement per unit would be $150. By engaging in this form of licensing, engineers from the 
WPI based company would then be able to focus more on enhancing the current technology 
rather than worrying about the burdens of starting a new company based on a single product. To 
generate interest from larger firms about potentially licensing the TEBV technology, WPI could 
publish articles in medical journals and magazines informing the industry of the technology and 
its beneficial effects.  
 The latter option to licensing the technology would be to generate a business plan and 
start a small “start-up” company. Although starting a new company is a massive task to 
undertake, it can have many benefits to the owners. One disadvantage to a start-up company is 
that it would be difficult to gather all of the assignees and inventors on the patent together to start 
a private business. If all members were not involved, an agreement for compensation to the 
members not included in the start-up company would need to be established.  
 There are two types of start-up companies that would be beneficial for the inventors to 
consider, namely LLC and LLP. A limited liability company (LLC) gives limited liability to its 
owners. This type of company is similar to a partnership in that the owners are allowed to utilize 
“pass through taxation.” In essence, this means that owners individually claim a share of the total 
companies profit taxes on their own individual tax returns.  
 The second of the potential start-up company scenarios is an LLP, commonly known as a 
limited liability partnership. Similar to the LLC, the LLP gives limited liability to its owners. 
Also, the partners are not responsible for each other’s misconduct should something go 
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drastically wrong. Finally, the LLP is covered under a different level of tax liability then that of a 
corporation.  
 After reviewing the potential scenarios, the author believes that the inventors of the 
TEBVs at WPI should consider producing a business plan and entering the industry as a start-up 
company. Through the analysis in the previous sections, the author believes that the TEBVs will 
provide a substantial benefit to the patients that receive the treatment. Also, the benefits of 
licensing are low due to the low royalty percentage. If the TEBVs perform like native blood 
vessels during, in-vivo testing, they could become the standard in the treatment of cardiovascular 
disease thus making the start-up company an extremely profitable venture. 
4.4.9 Health Insurance Reimbursement Coverage  
  
 Health insurance in the United States is defined as any program that assists in the 
payment of medical bills for qualifying patients. Health insurance can come from a multitude of 
mediums including but not limited to: private insurance firms, social insurance provided by the 
government, or welfare programs run by the government. In a report published in 2008 by the 
United States Census Bureau, approximately 85% of Americans are covered by health 
insurance.
38
  
 Assuming that the TEBVs produced by the method and product produced at WPI are 
approved for in vivo use by the FDA, there will need to be adequate health insurance 
reimbursement for patients receiving treatment. According to a study by Nicolas L’Heureux, co-
founder of Cytograft Tissue Engineering, the high costs associated with advanced therapeutic 
procedures make health insurance reimbursement a necessity.
5
 It is noted in this study that the 
FDA requires stringent safety and efficacy data to grant approval for clinical applications. It is 
duly noted that Medicare programs funded by the U.S. government demand that the product in 
71 
 
question shows cost effectiveness over time to prove that it is worth reimbursement. It is 
mentioned in L’Heureux’s study that there is a need for 4-6 years of data to prove a product is 
cost effective.
5
  
 L’Heureux’s study compares three similar tissue engineered products which currently 
receive health insurance reimbursement, namely Carticel produced by Genzyme, Apligraft 
produced by Novartis, and Dermagraft produced by Advanced BioHealing.
5
 In Table 14, the 
reimbursement levels are shown. It is interesting to note that the cost of Carticel is around 
$25,000.
39
 At this cost, the insurance reimbursement is about 70% of the total cost. It can be 
assumed that due to the similarity of the products (Table 14) relative to the product designed at 
WPI, WPI’s TEBVs are likely to receive a similar reimbursement.  
 
 
Company & Product Reimbursement Level (in U.S. dollars) 
Carticel, produced by Genzyme $17,600 
Apligraft, produced by Novartis $1,200 per 44cm
2 
Dermagraft, produced by Advanced BioHealing $535 per 37.5cm
2 
 
Table 14: Comparison of Reimbursement Levels for Three Tissue Engineered Products.5 
  
HCPCS Coding: Level I & Level II 
 
 In order for a product to be “market ready,” it must qualify for health insurance 
reimbursement. Once approved by the FDA through the steps outlined in section 4.4.3, a new 
medical product or device must be coded for medical billing through the Centers for Medicare 
and Medicaid Services (CMS). This is done through the healthcare common procedure coding 
system, more simply known as the HCPCS. There are two subunits of the HCPCS known as 
level I and level II.  
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 Level I, which is the current procedural terminology (CPT), is used to denote medical 
services and/or procedures that are performed by health care professionals. These codes are 
revised by the American Medical Association (AMA).
40
  
 Level II HCPCS is a coding system used to represent medical products, procedures, and 
supplies. It is important to note that the items covered in level II HCPCS are not covered by level 
I HCPCS. There are several types of HCPCS level II codes which include: 
 Permanent National Codes  
 Dental Codes 
 Miscellaneous Codes 
 Temporary National Codes 
 
 Permanent HCPCS level II codes are used by all private and public health insurance 
companies. The codes are regulated and monitored by the “CMS HCPCS Workgroup.” The 
Workgroup is comprised of members from each of the involved parties. Included in this group 
are private insurance agencies, insurance pricing, data analysis, coding, and Medicaid. The 
involved parties meet to discuss the needs of each other and whether the program is meeting 
those needs. The Workgroup is also in charge of adding new codes, revising existing codes, and 
deleting codes that are not being used.
40
 The TEBVs produced from the WPI device will be 
considered medical products and will fall subject to these level II codes.  
 Once the procedure is coded, health insurance providers will consider products or 
services for insurance reimbursement. Each insurance provider will have its own level of 
coverage for any given products or services. The specifications taken into consideration when a 
product is reviewed for reimbursement by public and private insurers include the effectiveness of 
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the device and whether the effectiveness of the device is worth the cost.
40
 In other words, the 
benefits versus the costs are analyzed. In direct relation to the effectiveness of the device versus 
the cost, L’Heureux states that the current method of treating vascular disease, through the 
harvest and implementation of the saphenous vein, has incidences of thrombosis up to 15% in the 
first 12 months post surgery. By eliminating this procedure, which causes complications through 
secondary harvest operations, health insurers can yield cost savings of more than $5,000 per 
patient.
5
 It is likely that the TEBVs produced by the WPI device will be coded by level II 
HCPCS and thus be eligible for health insurance reimbursement.  
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5 Conclusions and Recommendations  
 
 Worcester Polytechnic Institutes TEBVs have a promising future in both the medical 
supplies and devices industry and the manufactured pharmaceuticals industry. As stated in the 
results, over 800,000 patients globally receive coronary artery bypass grafts.
2
 With a potential 
market of this size, it is expected that TEBVs will have a high demand in the market place. 
Although the technology is currently still in the pre-clinical stage, the analyses in this report 
show that the TEBVs can be very successful in the cardiac market. It was determined in the cost 
analysis that the approximated cost to produce one TEBV with the WPI process is around 
$10,000. Economies of scale are the production cost breaks a company experiences due to 
expansion. In other words, this concept means that as a company expands, the unit price of the 
products produced decreases. It is expected that with a more streamlined process, WPI will be 
able to reduce this cost to produce. As seen in Figure 15 below, the concept of economies of 
scale is reviewed. 
 
 
Figure 15: Economies of Scale 
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Figure 15 clearly shows that as the output increases from “Q” to “Q1,” the cost decreases from 
“C” to “C1.” This illustrates that over time, as a company produces more products, the process 
will become more streamlined thus lowering overall cost. 
 One way that would reduce the cost to produce one TEBV is reducing the overall cost of 
the skin biopsy. As noted, a skin biopsy is around $5,000, which is half of the overall production 
cost. This could be done by having a professional work within the firm to extract the skin 
biopsies from the patients. Not only would this eliminate the shipping cost, but it would also 
reduce the company’s outsourcing costs.  
 Another factor that will need to be considered in the future is the testing. It is unknown, 
at this point, how many TEBVs will need to be tested for each patient in order to consider the 
TEBV safe for clinical use. For example, WPI may need to produce four TEBVs for “patient x” 
so that three can be used for testing. If one of these three fails, then WPI will have to start the 
process over to produce four new vessels to test. This discrepancy in the technical specifications 
of individual TEBVs may prove to be costly. Tests such as burst pressure, suture pull, and 
stretch/tear tests are all standard tests that the WPI TEBVs may be subject to.  
 In conclusion, with 800,000+ CABG procedures yearly, there are a number of patients 
who can potentially benefit from WPI’s TEBVs. Payback period is defined as the time it takes 
for the return on investment to pay out to the investors. It is impossible to calculate the time it 
will take to sell the required number of TEBVs to break-even; however, if the TEBVs are 
produced for the projected cost of $10,000, it is expected that with an initial investment of 
$100,000, the company will only need to sell 17 units to break-even on the initial investment. 
Based on the data collected and analyzed in this report, even if this estimate is off by a factor of 
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ten, the author recommends that the TEBVs produced at WPI’s Gateway Laboratories are a 
worthwhile venture to pursue further. 
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7 Glossary  
 
 
Allograft- A graft of tissue obtained from a donor of the same species. 
 
Autograft- A graft of tissue obtained from a patient and used in the 
same patient’s body. 
 
Centrifuge- A piece of equipment driven by an electric motor that 
puts an object in rotation around a fixed axis which applies force to the 
perpendicular axis. 
 
Competitive Advantage- A strategic advantage that one business has 
over another business within its competitive industry. 
 
Coronary Artery Bypass Graft (CABG)- A surgical procedure in 
which surgeons bypass the coronary artery due to coronary artery 
disease. 
 
Endothelial Cells- Cells that are part of the endothelium in the human 
body; Endothelium is the thin layer of cells lining the interior surface 
of blood vessels. 
 
Fibroblasts- Type of cell that synthesizes the extracellular matrix and 
collagen. 
 
Graft- Material, especially living tissue or an organ, surgically 
attached to or inserted into a bodily part to replace a damaged part or 
compensate for a defect.  
 
Graft vs Host Disease- A common complication in which functional 
immune cells within the body attack a graft due to its “foreign” nature. 
 
Market Capitalization- A measurement of size of a business 
enterprise equal to the share price times the number of shares 
outstanding of a publically traded company. 
 
Payback Period- Period of time required for the return on investment 
to repay the sum of the original investment. 
 
Plug and Play Kit- Refers to the ease of use of the device. This means 
that the device is usable by any individual capable of reading the user 
manual.  
 
Restenosis- The re-narrowing of a blood vessel/artery that has been 
previously treated. 
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Return on Investment (ROI)- Ratio of money gained or lost on an 
investment relative to the amount of money invested. 
 
Stent- An artificial tube inserted into a natural passage or conduit in 
the body to prevent or counteract a cardiovascular disease induced 
constriction of blood flow.  
 
Thrombosis- The formation of a blood clot within a blood vessel 
constricting flow of the circulatory system.  
 
Tissue Engineered Blood Vessel (TEBV)-A living biological blood 
vessel that shares the same or similar properties to that of native living 
tissues. TEBVs are designed by engineers. 
 
Triglycerides- One of the three fatty acids in which contributes to the 
blockage of arteries causing cardiovascular disease.  
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8 Appendices 
 
8.1 Rough Design of Motor Encasing Unit Sent to Manufacturing Companies 
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8.2 Biomedical Engineering Department Problem Statement 
 
Market and Business Analysis of a Cellular Assembly Device for Tissue 
Engineered Blood Vessel Fabrication 
 
MQP:  Brent Evansen, AY 2010-2011 
Advisors:  H. Vassallo, M. Rolle 
 
Technical Background 
Tissue engineering has emerged as a promising approach to creating blood vessel 
equivalents that can be used surgically to replace diseased or damaged blood vessels.  
Tissue engineered blood vessels (TEBV) may also be valuable as unique 3D in vitro 
models of human vascular structure and function and powerful new tools to advance 
vascular disease research. 
Current methods for producing TEBV have primarily focused on utilizing a synthetic or 
natural scaffold material that can be seeded with cells to create a living vascular tissue 
equivalent.  Alternatively, TEBV generated entirely from living cells (without exogenous 
scaffold materials) may have unique advantages, including a lower incidence of 
infection, a lack of foreign scaffold materials, more favorable mechanical properties 
(more compliant, less stiff) and greater contractile responsiveness.  However, there are 
many challenges associated with creating “scaffold-free” cell-based TEBV, including the 
need for 1) a device or technique that reproducibly assembles cells into a tube shape, 
2) the large volume of cells needed initially to create tubular tissues, and 3) the long 
culture time required for cells to synthesize structural proteins (extracellular matrix) and 
mature into a strong, transplantable tissue. 
To address these needs, a WPI BME MQP Team (Burford, Jones, Soderbom, Sullivan; 
Advisor: Rolle1) designed a device that uses centrifugal force to rapidly assemble a 
large number of individual cells suspended in cell culture medium into a cohesive, tube-
shaped, 3D tissue within a few days.  To date, the technical focus of the project has 
been on creating, validating, and refining the device and evaluating the effects of 
different manufacturing and operational parameters of the device on the structure and 
function of the resulting tissue tubes.  An invention disclosure describing the device and 
method of cellular assembly to form tube-shaped tissues was filed with the WPI Office 
of Technology Transfer in September 2010. 
The ultimate technical goal of this project is to create a device that is inexpensive 
and easy to use which rapidly and reliably converts a suspension of cells into a 
robust, tube-shaped tissue.   
 
Marketing Problem Statement 
Assuming that the above technical goal can be met, we would like to refine the device 
such that it could be packaged and sold as an inexpensive device or “kit” to enable its 
user (scientists, surgeons, etc.) to inject or infuse a suspension of cells of their interest 
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into the device and create a living, cell-based, tube-shaped tissue for research or 
therapeutic purposes.   
To attract funding to start a company to manufacture these devices, we need to 
generate a business plan detailing the need for the product, the size and scope of the 
potential market for our product, the costs to produce (manufacture, sterilize, package, 
etc.) the product, identification and analysis of the competition, and any other 
challenges and opportunities unique to the manufacturing and marketing of our device.  
Ideally, this analysis will lead to a report and presentation that could be “pitched” to 
venture capitalists to attract funding to start our company. 
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8.3 WPI Kit Break-Even Chart 
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8.4 WPI TEBV Break-Even Chart 
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